New hope for tough childhood cancers: targeted drug combo under study
NCT ID NCT01946529
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of drugs (temsirolimus, temozolomide, and irinotecan) for children and young adults with high-risk Ewing sarcoma or desmoplastic small round cell tumors. Participants are split into standard-risk and high-risk groups, with high-risk patients receiving the experimental therapy first. The goal is to see if this approach shrinks tumors and improves long-term survival, with follow-up lasting 10 years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DESMOPLASTIC SMALL ROUND CELL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive antibody targets rare childhood cancer
- New immunotherapy targets genetic flaw in rare childhood cancers
- New hope for tough tumors: Half-Matched bone marrow transplant trial
- New drug cocktail aims to keep childhood cancers at bay
- New drug cocktail aims to tackle tough sarcomas in young patients
- New cocktail of four drugs aims to tackle childhood cancers that Won't go away